(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Developmental Disabilities Translational Research Lab, directed by
Tori Schaefer, PhD, focuses on developing new targeted drug treatments in
developmental disabilities. We utilize mouse models of fragile X syndrome, Angelman syndrome, and autism to identify novel targets. The lab tests the effectiveness of new compounds and repurposed drugs for the treatment of behavior, molecular, and cellular abnormalities associated with these disorders.
We are also developing novel biomarkers of disease pathophysiology and treatment response that will hopefully lead to more personalized treatment approaches and successful outcomes for children and adults with developmental disabilities.
Dominick K, Wink LK, McDougle CJ, Erickson CA. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):397-401.
Adler BA, Wink LK, Early M, Shaffer R, Minshawi N, McDougle CJ, Erickson CA. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. Autism. 2015 Jan;19(1):102-6.
Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014 Dec;59:220-8.
Wink LK, O'Melia AM, Shaffer RC, Pedapati E, Friedmann K, Schaefer T, Erickson CA. Intranasal ketamine treatment in an adult with autism spectrum disorder. J Clin Psychiatry. 2014 Aug;75(8):835-6.
Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014 Apr;44(4):958-64.
Erickson CA, Wink LK, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, McDougle CJ. Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord. 2014 Apr;44(4):981-7.
Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, Erickson CA. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):78-82.
Tori Schaefer, PhDResearch Associate
Mailing Address:Division of Psychiatry Cincinnati Children’s Hospital Medical Center3430 Burnet Ave.MLC 4002Cincinnati, OH 45229
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.